Arrowhead Pharma acquires FDA rare pediatric disease priority review voucher - ARWR News | RalliesArrowhead Pharma acquires FDA rare pediatric disease priority review voucher
A
ARWR• Arrowhead acquires priority review voucher for planned plozasiran filing
- Arrowhead Pharmaceuticals agreed to acquire a U.S. FDA Rare Pediatric Disease Priority Review Voucher from an undisclosed third party.
- The voucher is slated for a planned plozasiran sNDA to expand use into severe hypertriglyceridemia, with submission expected before end-2026.
- Priority Review would cut the FDA review goal to six months from 10 months under standard review.
- Deal closing is subject to the Hart-Scott-Rodino waiting period and customary conditions.
NRGV
•
